Yanping Zhong1,2, Jinsong Liu1, Xiaoran Li1, Shannon N Westin3, Anais Malpica1, Barrett C Lawson1, Sanghoon Lee4, Bryan M Fellman5, Robert L Coleman3, Anil K Sood3, Nicole D Fleming3. 1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2. Department of Pathology, The First Hospital of Jilin University, Changchun 130021, Jilin, China. 3. Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4. Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5. Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
Background: The impact of chemotherapy response score (CRS) on prognosis has varied among studies. We addressed the prognostic significance of CRS and the prognostic value of previously undescribed histologic features using a cohort of 245 patients. Methods: Retrospective study in patients with advanced extrauterine high-grade serous carcinomas treated with neoadjuvant chemotherapy followed by interval tumor reductive surgery from 1990 to 2018 in our hospital. Gynecologic pathologists assessed tumor CRS and other histologic features. Clinical information was collected, and multivariate analyses were conducted. Results: A modified 2 tier CRS (CRS 1/2 versus CRS 3) was significantly associated, independent of scoring site (omental versus adnexal), with overall survival (OS) (omentum, p = 0.018; adnexa, p = 0.042; entire cohort, p = 0.002) and progression-free survival (PFS) (p = 0.021, p = 0.035, and p = 0.001, respectively). On multivariate survival analysis, 2 tier CRS, oncocytic change, inflammation, and desmoplasia were significant for OS (p = 0.034, p = 0.020, p = 0.007, and p = 0.010, respectively). Likewise, 2 tier CRS, inflammation, and desmoplasia were significant for PFS (p = 0.012, p = 0.003, p = 0.011, respectively). Conclusions: The modified 2 tier CRS was significantly associated with survival, independent of scoring site. Additional histologic features including oncocytic change, inflammation, and desmoplasia can also predict patient outcomes.
Background: The impact of chemotherapy response score (CRS) on prognosis has varied among studies. We addressed the prognostic significance of CRS and the prognostic value of previously undescribed histologic features using a cohort of 245 patients. Methods: Retrospective study in patients with advanced extrauterine high-grade serous carcinomas treated with neoadjuvant chemotherapy followed by interval tumor reductive surgery from 1990 to 2018 in our hospital. Gynecologic pathologists assessed tumorCRS and other histologic features. Clinical information was collected, and multivariate analyses were conducted. Results: A modified 2 tier CRS (CRS 1/2 versus CRS 3) was significantly associated, independent of scoring site (omental versus adnexal), with overall survival (OS) (omentum, p = 0.018; adnexa, p = 0.042; entire cohort, p = 0.002) and progression-free survival (PFS) (p = 0.021, p = 0.035, and p = 0.001, respectively). On multivariate survival analysis, 2 tier CRS, oncocytic change, inflammation, and desmoplasia were significant for OS (p = 0.034, p = 0.020, p = 0.007, and p = 0.010, respectively). Likewise, 2 tier CRS, inflammation, and desmoplasia were significant for PFS (p = 0.012, p = 0.003, p = 0.011, respectively). Conclusions: The modified 2 tier CRS was significantly associated with survival, independent of scoring site. Additional histologic features including oncocytic change, inflammation, and desmoplasia can also predict patient outcomes.
Authors: Andrea Ambrosini-Spaltro; Fabrizio Salvi; Christine M Betts; Giovanni P Frezza; Antonio Piemontese; Pietro Del Prete; Cristina Baldoni; Maria P Foschini; Giuseppe Viale Journal: Virchows Arch Date: 2005-12-20 Impact factor: 4.064
Authors: H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Helena M Ditzel; Kyle C Strickland; Emily E Meserve; Elizabeth Stover; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Michael G Muto; Joyce F Liu; Colleen Feltmate; Neil Horowitz; Ross S Berkowitz; Mamta Gupta; Jonathan L Hecht; Douglas I Lin; Kirsten M Jochumsen; William R Welch; Michelle S Hirsch; Bradley J Quade; Kenneth R Lee; Christopher P Crum; George L Mutter; Marisa R Nucci; Brooke E Howitt Journal: Int J Gynecol Pathol Date: 2019-05 Impact factor: 2.762
Authors: Barrett C Lawson; Elizabeth D Euscher; Roland L Bassett; Jinsong Liu; Preetha Ramalingam; YanPing Zhong; Nicole D Fleming; Anais Malpica Journal: Am J Surg Pathol Date: 2020-02 Impact factor: 6.298